Ong KL, Wu L, Januszewski AS, et al. - The present study was undertaken to investigate determinants of circulating levels of an adipocyte-fatty acid-binding protein (A-FABP) and lipocalin-2 (LCN2), their associations with cardiovascular disease (CVD) and microvascular events, and impacts of fenofibrate in type 2 diabetes (T2D). Researchers tested A-FABP and LCN2 in baseline plasma from 2,000 T2D adults in a Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial sub-study and correlate thereof ascertained. They also assessed in a subset (n=200) adipokines on-trial. This study's findings demonstrate that baseline plasma A-FABP and LCN2 levels were associated with concurrent CVD risk factors, and on-trial chronic complications, likely mediated via traditional risk factors. It was shown that Fenofibrate elevated A-FABP modestly but did not influence LCN2 levels.